Literature DB >> 30499391

Chemotherapeutic Potential of Monensin as an Anti-microbial Agent.

Vinoth Rajendran1, Hema Saranya Ilamathi1,2,3, Suparna Dutt4, T S Lakshminarayana1,5, Prahlad C Ghosh1.   

Abstract

Monensin is a lipid-soluble naturally occurring bioactive ionophore produced by Streptomyces spp. Its antimicrobial activity is mediated by its ability to exchange Na+ and K+ ions across the cell membrane thereby disrupting ionic gradients and altering cellular physiology. It is approved by Food and Drug Administration as a veterinary antibiotic to treat coccidiosis. Besides veterinary applications, monensin exhibits a broad spectrum activity against opportunistic pathogens of humans such as bacteria, virus, fungi and parasites in both drug sensitive and resistant strains. This ionophore can selectively kill pathogens with negligible toxic effect on mammalian cells. In this review, we discuss the therapeutic potential of monensin as a new broad-spectrum anti-microbial agent that warrants further studies for clinical use. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Anti-microbial; Chemotherapy; Drug-resistant; Ionophores; Monensin; Pathogens.

Mesh:

Substances:

Year:  2018        PMID: 30499391     DOI: 10.2174/1568026619666181129141151

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Boromycin Has Potent Anti-Toxoplasma and Anti-Cryptosporidium Activity.

Authors:  Jaypee Abenoja; Alexis Cotto-Rosario; Roberta O'Connor
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.938

2.  Factors governing the competition between group IA and IB cations for monensin A: a DFT/PCM study.

Authors:  Todor Dudev; Diana Cheshmedzhieva; Radoslava Dimitrova; Peter Dorkov; Ivayla Pantcheva
Journal:  RSC Adv       Date:  2020-02-04       Impact factor: 3.361

Review 3.  Marine Actinomycetes, New Sources of Biotechnological Products.

Authors:  Sveta V Jagannathan; Erika M Manemann; Sarah E Rowe; Maiya C Callender; William Soto
Journal:  Mar Drugs       Date:  2021-06-25       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.